ClinicalTrials.gg
RecruitingNCT05410106VAP-XUpdated Mar 25, 2024

Ventilator Aspiration With PneuX (PneuX vs Standard Care Feasibility RCT)

An interventional study of PneuX Endotracheal Tube and Standard care (Taperguard, Covidien) in Ventilator Associated Pneumonia, Aspiration and Infections, sponsored by Cardiff and Vale University Health Board. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-25.

Sponsored by Cardiff and Vale University Health Board · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Dec 2022; still recruiting 3 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom — 2 open to participants now, 3 under way, none of them phase 3. Pneumonia, Ventilator-Associated · United Kingdom.

Started
2022
with 1 other
No phase
2 of 11
1 open now
Registered
9th of 11
by date
Lead sponsor
1 of 11
Cardiff and Vale University Health Board

Among the 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom, this one is one of 2 that started in 2022, is one of 2 with no phase, and was the 9th registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

2 of the 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Pneumonia, Ventilator-Associated with a site in United Kingdom, or all of them as a file.
02

Study summary

This is a single centre, open-label, feasibility randomised controlled trial. The study aims to assess the feasibility of conducting an RCT to compare the PneuX ETT with standard care in hospitalised patients requiring mechanical ventilation. The patient population for this study are those who are experiencing critical illness requiring intubation and ventilatory support. Patients will be randomised in equal proportions into one of 2 arms: to be intubated using a Venner PneuX Endotracheal Tube (ETT) or using the standard tube. For this feasibility study, a total of 50 patients will be randomised into two groups (25 in each). All patients will be recruited at a single site (University Hospital of Wales, part of Cardiff \& Vale UHB). The study will investigate several feasibility measures including recruitment, delivery of the intervention (including device-related adverse events), acceptability and adherence to the intervention and sampling, use of Peptest to measure microaspiration events, rate of pepsin positive samples, rate of tracheobronchial colonisation, volume of sub-glottic aspirate, rate of VAP, length of ICU and hospital stay, demonstrate the validity of study documentation and provide preliminary data for 50 patients. The data will inform the pilot and main phase of the study.

03

Conditions studied

  • Ventilator Associated Pneumonia
  • Aspiration
  • Infections
  • Ventilator Lung

Keywords

  • Ventilator Associated Pneumonia
  • endotracheal tube
  • Aspiration
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years old (no upper age)
  • Patient required endotracheal intubation
  • Expect to remain intubated for 24 hours post randomisation

Exclusion criteria

Exclusion Criteria:

  • The person intubating the patient assesses that the patient has already aspirated.
  • GCS 7 or less on presentation to hospital
  • Patient is pregnant
  • Patient has tracheostomy
  • Patient has gastrectomy
  • Patients who have been intubated prior to arrival at hospital
  • Patients who are already endotracheally intubated and require a tube change.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    PneuX endotracheal tube

    Patients will be intubated using the PneuX endotracheal tube system

    Device: PneuX Endotracheal Tube

  • Active comparator
    Standard care

    Patients will be intubated using standard endotracheal tube (Taperguard, Covidien).

    Device: Standard care (Taperguard, Covidien)

Interventions

  • DevicePneuX Endotracheal Tube

    The PneuX Endotracheal Tube is a CE marked device produced by Venner. The purpose of this product is to provide invasive ventilation for patients in the ICU. The defining features of the intervention treatment are the multi-modal approach to prevent microaspiration during long term ventilation.

    Also known as: Venner PneuX System

  • DeviceStandard care (Taperguard, Covidien)

    Standard care is to intubate patient using the Taperguard endotracheal tube (ETT). The Taperguard ETT is designed with a tracheal shaped cuff made of PVC. This has a single lumen subglottic port.

06

What researchers measure

Primary outcomes

  1. To assess if a recruitment rate of 50 patient annually is achievable and identify any barriers to recruitment

    The recruitment rate will be assessed using the "screening and recruitment log" which will record the number of patients recruited each month and reasons for non-recruitment will be described

    Time frame: Through study completion, an average of 1 year

Secondary outcomes

  1. To assess the feasibility of delivering the study intervention

    Any issues experienced when using the study device at any point during the study will be recorded in the CRF, including device-related complications.

    Time frame: Duration of study treatment (typically 4-7 days)

  2. Number of participants with a failed pepsin test

    Any issues such as failed sampling or failed testing will be recorded in case report form

    Time frame: Duration of study treatment (typically 4-7 days)

  3. Number of participants with a positive pepsin tracheal aspirate sample using Peptest

    The proportion of tracheal aspirate samples which are positive for the presence of pepsin using the Peptest test

    Time frame: Duration of study treatment (typically 4-7 days)

  4. Volume of sub-glottic aspirates

    The volume of the sub-glottic aspirates will be measured every 24 hours

    Time frame: Duration of study treatment (typically 4-7 days)

  5. Rate of tracheobronchial colonization

    Tracheobronchial colonization (no. colony forming units/ml) present in sputum samples will be measured by culture on days 3 and 7

    Time frame: Duration of study treatment (typically 4-7 days)

  6. Proportion of patients who require antibiotics

    The following will be assessed: antibiotic prescribed, indication for use, number of days administered

    Time frame: 28 days

  7. Rate of Ventilator Associated Pneumonia (VAP)

    Number of patients with VAP diagnosis. Clinical Pulmonary Infection Score (CPIS) used to predict VAP. CPIS \>6 will be used to define confirmation of VAP. Measured daily after 48 hours of intubation

    Time frame: 28 days

  8. Time spent on the ventilator

    Days spent with mechanical ventilation in ICU (from time/date of intubation to time/date of extubation or 28 days)

    Time frame: Duration of study treatment (typically 4-7 days)

  9. Number of days spent in ICU and hospital

    Length of stay in ICU and length of stay in hospital measured in days from ventilation

    Time frame: 28 days

  10. Rate of in-hospital mortality

    Number of patients who die in hospital up to 28 days after entry into ICU

    Time frame: 28 days

  11. Rate of compliance with measuring and documenting cuff pressure

    Documentation of cuff pressures in both arms of study. Cuff pressure in standard care will be measured every 12 hours. Assessment of intervention arm will have documentation that pressure has been maintained hourly either via the continual cuff pressure monitor or manually.

    Time frame: Duration of study treatment (typically 4-7 days)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2022 (actual). Primary completion is estimated for Dec 2024, 24 months after the start.

Of 82 non-industry interventional studies with no phase under Pneumonia, Ventilator-Associated, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 36. This study's planned 24 months is above that.

Counting every sponsor, half of 83 studies reached it within 20 months; a quarter within 10 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2022
First posted
Jun 8, 2022
StartActual
Dec 5, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
Mar 25, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 25, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05410106
Lead sponsor
Cardiff and Vale University Health Board
Collaborators
Cardiff University
Responsible party
Sponsor
First posted
Jun 8, 2022
Start date
Dec 5, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
Mar 25, 2024

Study contacts

Judith White
Contact
judith.white3@wales.nhs.uk
02921844771
Rhys Morris
Contact
Rhys.Morris@wales.nhs.uk
0292144772
Matthew Wise
study chair · Cardiff and Vale University Health Board
Matthew Wise
principal investigator · Cardiff and Vale University Health Board

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion